New Trade for January 21st, 2021

Stocks are looking to set new record highs today, the first official full day of Joe Biden’s presidency.  President Biden is expected to sign 10 pandemic-fighting orders today.  The Biden administration has promised to try to turn the Covid-19 pandemic around and drastically speed up the pace of vaccinating Americans against the virus.  

In 2020 biotech stocks garnered  lots of attention.  Some experts say we’re in “the golden age of biotechnology.” Scientific advances are opening up possibilities for the treatment and prevention of diseases that could only have been imagined in the past.

This golden age is also presenting tremendous opportunities for investors. Biotech stocks offer the potential for huge long-term returns.  The best biotech stocks to buy right now boast strong pipelines, and some already have winning drugs on the market.

Today’s trade alert features a biotech investment that experts say could stack on major gains in the months and years to come.

Regeneron Pharmaceuticals (REGN), responsible for drugs such as macular degeneration Eylea and arthritis treatment Kevzara, made headlines in 2020 for the monoclonal antibody cocktail REGN-CoV2, which was used to treat President Donald Trump’s COVID-19 infection.

It also is responsible for an impressive system for drug discovery. Velocisuite is a collection of techniques, based on mouse DNA models, that lets researchers quickly test drug compounds.

Regeneron also has collaborated on a number of drugs, including the aforementioned Libtayo and Dupixent, for instance, as well as Kevzara. As part of Sanofi’s exit from owning Regeneron, the two companies have restructured their collaborations on Kevzara and Praluent, a drug to treat high cholesterol that Regeneron feels will break even in 2021.

While clearly REGN-CoV2 has boosted the stock, the company itself has enjoyed double-digit revenue growth on average over the past few years. And it could continue to serve investors well as one of the best biotech stocks for 2021.

Canaccord Genuity analyst John Newman has a “Buy” rating and $700 price target on shares. He writes that “We are encouraged by REGN-COV2 data and see a strong need in the seronegative patient population. We also believe that the drug can be used at a lower dose, extending dosing capacity.”Credit Suisse analysts have a $725 price target on shares, saying they also believe the company could get excellent results from the drug at lower dosages. They also don’t see LY-CoV555, a similar compound from Eli Lilly, as a threat. “We do not see this as a zero-sum game,” the analysts add.

Where to invest $1,000 right now...

Before you consider buying Regeneron, you'll want to see this.

Investing legend, Keith Kohl just revealed his #1 stock for 2022...

And it's not Regeneron.

Jeff Bezos, Peter Thiel, and the Rockefellers are betting a colossal nine figures on this tiny company that trades publicly for $5.

Keith say’s he thinks investors will be able to turn a small $50 stake into $150,000.

Find that to be extraordinary?

Click here to watch his presentation, and decide for yourself...

But you have to act now, because a catalyst coming in a few weeks is set to take this company mainstream... And by then, it could be too late.

Click here to find out the name and ticker of Keith's #1 pick...